OGEN — ORAGENICS INC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1174940 ·
Last close
$0.49
Market Cap
$2.21M
52W High
$1.45
52W Low
$0.48
ADV30
35,900
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -2,255,927 | -2,201,243 | 7,489,636 | 6,107,078 | 1,307,878 |
| Dec 2025 | 0 | — | -2,498,301 | -2,286,870 | 10,067,764 | 4,399,726 | 1,786,359 |
| Sep 2025 | 0 | — | -3,123,773 | -3,066,589 | 12,705,544 | 11,403,766 | 2,874,108 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,334,941
Investing CF
$4,000,000
Financing CF
$12,020,941
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.22
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-228,829,902
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-9,395,742
Pretax Income TTM
$-9,986,272
Interest Exp TTM
$590,530
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,362,503 | -9,842,487 | 10,067,764 | 1,786,359 | 8,281,405 | -9,246,387 |
| Dec 2024 | 0 | -10,558,815 | -10,567,918 | 1,472,510 | 1,684,395 | -211,885 | -8,597,382 |
| Dec 2023 | 0 | -20,904,903 | -20,655,737 | 4,966,335 | 1,798,181 | 3,168,154 | -7,290,880 |
| Dec 2022 | 0 | -14,420,768 | -14,288,389 | 14,758,025 | 1,748,723 | 13,009,302 | -15,228,483 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCYN | PROCYON CORP | $2.20M | $0.27 | — |
| CVSI | CV Sciences, Inc. | $2.26M | $0.01 | — |
| NXTS | Nexentis Technologies Inc. | $2.14M | $1.47 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.35M | $4.01 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $2.35M | $0.16 | — |
News headlines (Yahoo Finance, 1h cache)
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
2026-09-16 12:30 · Yahoo
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
2026-08-28 20:25 · Yahoo
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
2026-07-07 12:30 · Yahoo
ORAGENICS PROVIDES INVESTOR UPDATE
2026-05-18 12:30 · Yahoo
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
2026-05-07 12:30 · Yahoo
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
2026-05-05 12:30 · Yahoo
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-13 12:30 · Yahoo
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-20 13:00 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
2026-05-19 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.